申请人:Sankyo Company, Limited
公开号:US05436242A1
公开(公告)日:1995-07-25
Compounds of formula (I): ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkylthio, haloalkylthio, amino, alkanoyl, haloalkanoyl, carboxy, alkoxycarbonyl, carbamoyl, cyano, nitro, alkanesulfonyl, haloalkanesulfonyl or sulfamoyl; R.sup.2 is 5,6-dihydro-1,4,2-dioxazin-3-yl; R.sup.3 is hydrogen, hydroxy, optionally substituted alkoxy, aralkyloxy, alkanoyloxy, alkenoyloxy, cycloalkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aralkyloxycarbonylxy, phthalidyloxy, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy, optionally substituted amino or nitro; Y is --NH-- or oxygen or sulfur; n is 1 to 5; and tautomers and salts of said compounds of formula (I), have the ability to inhibit blood platelet aggregation, and can thus be used for treatment and prophylaxis of thrombosis and embolisms.
式(I)的化合物:##STR1## 其中R.sup.1是氢、烷基、卤素、卤代烷基、羟基、烷氧基、卤代烷氧基、烷硫基、卤代烷硫基、氨基、烷酰基、卤代烷酰基、羧基、烷氧羰基、氨基甲酰基、氰基、硝基、烷基磺酰基、卤代烷基磺酰基或磺酰胺基;R.sup.2是5,6-二氢-1,4,2-二噁嗪-3-基;R.sup.3是氢、羟基、可选取代烷氧基、芳基烷氧基、烷酰氧基、烯酰氧基、环烷基羧酸酯基、芳基羧酸酯基、烷氧羰基酯基、芳基烷氧羰基酯基、邻苯二甲酰氧基、(5-甲基-2-氧代-1,3-二噁吖啶-4-基)甲氧基、(5-苯基-2-氧代-1,3-二噁吖啶-4-基)甲氧基、可选取代氨基或硝基;Y是--NH--或氧或硫;n为1到5;式(I)化合物的互变异构体和盐具有抑制血小板聚集的能力,因此可用于治疗和预防血栓和栓塞。